Worldwide Breast Biopsy Industry to 2025 - Featuring Hologic, Danaher & Argon Medical Among Others
DUBLIN, Oct. 12, 2020 /PRNewswire/ -- The "Breast Biopsy Market by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.
The global breast biopsy market is projected to reach USD 1,094 million by 2025 from USD 725 million in 2020, at a CAGR of 8.6% during the forecast period.
The factors driving the growth of the market are growing incidence of breast cancer, increasing demand for minimally invasive and non-invasive procedures, and increasing number of breast cancer screening programs. However, stringent regulatory approval procedures and product recalls are expected to restrain the growth of this market in the coming years.
Breast cancer is among the most common diseases affecting women in developed as well as developing countries. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women across the globe. The increasing number of breast cancer cases has forced governments across the globe to raise awareness regarding the importance of early detection of breast cancer. Thus, surge in breast cancer incidence and favorable government guidelines are expected to support market growth.
The breast biopsy market is witnessing loss of business and the trend is expected to continue till December 2020. Unfavorable changes in regulations and guidelines are hampering the growth of this industry. Major regulatory authorities across the globe (such as CDC, WHO, MHRA, TGA, and EMA) have identified that breast cancer patients are at greater risk of COVID-19 infection than healthy adults. Thus, screening, diagnostic exams, and surgical procedures are being severely restricted or postponed at hospitals and breast centers. This is expected to cause disruption in the breast cancer diagnosis as well as treatment market.
Assay Kits: The fastest-growing segment of breast biopsy market over the forecast period
Based on product, the breast biopsy market is segmented into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other products. In the past two decades, personalized medicine has increasingly been recognized for its ability to detect cancer (including breast cancer) early and accurately. Promising role of liquid biopsy in the field of personalized medicine is expected to boost the segment growth.
Core needle biopsy: The largest sub-segment of needle breast biopsy segment
Based on type, the breast biopsy market is segmented into needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. In 2019, the needle breast biopsy held a major share of the breast biopsy market. Rising adoption of core needle biopsy by healthcare professionals due to advantages such as high sensitivity and specificity and technological advancements are driving growth of the segment.
Early cancer screening: The dominating application segment of breast biopsy market
Based on application, the breast biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The early cancer screening segment accounted for largest share of the breast biopsy market in 2019. The major share of the segment is attributed to the rising incidence of breast cancer, growing awareness about early cancer screening, and development of breast cancer screening programs.
North America: The largest share contributing regional segment of the global breast biopsy market in 2019
The breast biopsy market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. North America accounted for a major share of the breast biopsy market in 2019. The large share of the region can be attributed to the early adoption of newer breast biopsy technologies, ongoing technological advancements, rising breast cancer incidence, and the rapidly increasing aging population that is more prone to developing breast cancer.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Breast Biopsy: Market Overview
4.2 Geographic Analysis: Breast Biopsy Market, by Product and Region
4.3 Geographic Analysis: Needle Breast Biopsy Market, by Type and Region
4.4 Liquid Breast Biopsy Market, by Guidance
4.5 Geographic Analysis: Breast Biopsy Market, by Application and Region
4.6 Geographic Snapshot of the Breast Biopsy Market
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Incidence of Breast Cancer
5.2.1.2 Increasing Number of Breast Cancer Screening Programs
5.2.1.3 Increasing Demand for Minimally Invasive and Non-Invasive Procedures
5.2.1.4 Growing Awareness Regarding Early Detection of Breast Cancer
5.2.1.5 Improved Reimbursement Scenario
5.2.2 Restraints
5.2.2.1 Risk of Infections Associated with the Use of Biopsy Needles
5.2.2.2 Stringent Regulatory Approval Procedures
5.2.2.3 Product Recalls
5.2.3 Opportunities
5.2.3.1 Emerging Economies Offer High Growth Potential
5.2.3.2 Emergence of Liquid Biopsy and Promising Clinical Trials
5.2.3.3 Increasing Public-Private Investments and Funding
5.2.4 Challenges
5.2.4.1 Underdeveloped Healthcare Infrastructure and Dearth of Resources in Developing Countries
5.3 Value Chain Analysis
5.4 Ecosystem: Breast Biopsy Market
5.5 Technology Analysis
5.6 Impact of COVID-19 on Breast Biopsy Market
6 Breast Biopsy Market, by Product
6.1 Introduction
6.2 Biopsy Needles
6.2.1 Technological Advancements to Drive Revenue Growth
6.2.2 Biopsy Needles Market Split, by Type, 2018-2025 (USD Million)
6.2.3 Biopsy Needles Market Split, by Guidance, 2018-2025 (USD Million)
6.2.4 Biopsy Needles Market Split, by Application, 2018-2025 (USD Million)
6.3 Guidance Systems
6.3.1 Procedural Advantages of Guided Biopsies to Fuel Rapid Market Expansion
6.3.2 Guidance Systems Market Split, by Type, 2018-2025 (USD Million)
6.3.3 Guidance Systems Market Split, by Guidance, 2018-2025 (USD Million)
6.3.4 Guidance Systems Market Split, by Application, 2018-2025 (USD Million)
6.4 Biopsy Tables
6.4.1 Increasingly Used to Perform Stereotactic Biopsy Procedures
6.4.2 Biopsy Tables Market Split, by Type, 2018-2025 (USD Million)
6.4.3 Biopsy Tables Market Split, by Guidance, 2018-2025 (USD Million)
6.4.4 Biopsy Tables Market Split, by Application, 2018-2025 (USD Million)
6.5 Assay Kits
6.5.1 Product Approval and Launches Driving Segment Growth
6.5.2 Assay Kits Market Split, by Type, 2018-2025 (USD Million)
6.5.3 Assay Kits Market Split, by Guidance, 2018-2025 (USD Million)
6.5.4 Assay Kits Market Split, by Application, 2018-2025 (USD Million)
6.6 Liquid Biopsy Instruments
6.6.1 Ongoing Research and Clinical Trials Expected to Deliver Novel Solutions in the Market
6.6.2 Liquid Biopsy Instruments Market Split, by Type, 2018-2025 (USD Million)
6.6.3 Liquid Biopsy Instruments Market Split, by Guidance, 2018-2025 (USD Million)
6.6.4 Liquid Biopsy Instruments Market Split, by Application, 2018-2025 (USD Million)
6.7 Localization Wires
6.7.1 Most Commonly Used to Locate Breast Abnormalities and Lumps
6.7.2 Localization Wires Market Split, by Type, 2018-2025 (USD Million)
6.7.3 Localization Wires Market Split, by Guidance, 2018-2025 (USD Million)
6.7.4 Localization Wires Market Split, by Application, 2018-2025 (USD Million)
6.8 Other Products
6.8.1 Rising Patient Population and Increasing Adoption of Biopsy Procedures to Support Segment Growth
6.8.2 Other Products Market Split, by Type, 2018-2025 (USD Million)
6.8.3 Other Products Market Split, by Guidance, 2018-2025 (USD Million)
6.8.4 Other Products Market Split, by Application, 2018-2025 (USD Million)
7 Breast Biopsy Market, by Type
7.1 Introduction
7.2 Needle Breast Biopsy
7.2.1 Core Needle Biopsy
7.2.1.1 Procedural Advantages of Guidance System-Based Biopsy to Drive Revenue Growth
7.2.2 Vacuum-Assisted Biopsy (Vab)
7.2.2.1 Technological Advantages Supporting Growth of Segment
7.2.3 Fine Needle Aspiration Biopsy (FNAB)
7.2.3.1 Increasingly Being Replaced by Core Needle Biopsy Procedures
7.3 Open Surgical Breast Biopsy
7.3.1 Excisional
7.3.1.1 Risk of Post-Operative Complications Hindering Growth of Segment
7.3.2 Incisional
7.3.2.1 Performed When Size of Tumor is Quite Large
7.4 Liquid Breast Biopsy
7.4.1 Circulating Tumor Cells
7.4.1.1 Difficult to Identify Limited Presence in Blood Sample
7.4.2 Circulating Tumor DNA (Ctdna)
7.4.2.1 Promising Blood-Based Biomarker to Monitor Disease StatUS
7.4.3 Other Biomarkers
7.4.3.1 Cell-Free Mrna, Mirna, and Tumor-Educated Platelets (Tep) Used for Early Detection
8 Breast Biopsy Market, by Guidance
8.1 Introduction
8.2 Image Guided Biopsy
8.2.1 Mammography-Guided Stereotactic Biopsy
8.2.1.1 Increasing Government-Initiated Breast Screening Programs to Drive Segment Growth
8.2.2 Ultrasound-Guided Biopsy
8.2.2.1 Advantages of Technique Resulting in Rising Adoption
8.2.3 Mri Guided Biopsy
8.2.3.1 High Cost and Low Specificity Affecting Segment Growth
8.2.4 Other Guidance Techniques
8.2.4.1 Ongoing Research and Clinical Trials Creating More Opportunities in the Market
8.3 Liquid Biopsy
8.3.1 Pcr-Based Biopsy
8.3.1.1 Expected to Hold Major Share of Market Over Forecast Period
8.3.2 Ngs-Based Biopsy
8.3.2.1 Technological Advancements and Advantages Expected to Drive Growth
8.3.3 Microarray-Based Biopsy
8.3.3.1 Ongoing Research and Promising Results Expected to Drive Segment Growth
9 Breast Biopsy Market, by Application
9.1 Introduction
9.2 Early Cancer Screening
9.2.1 Growing Awareness About Early Cancer Detection Driving Segment Growth
9.3 Therapy Selection
9.3.1 Emergence of Plasma-Based Genotyping Expected to Drive Growth in Developed Countries
9.4 Treatment Monitoring
9.4.1 Liquid Biopsy Gaining Attention for Real Time Treatment Monitoring
9.5 Recurrence Monitoring
9.5.1 Unmet Clinical Needs Creating Opportunities for Players in the Market
10 Breast Biopsy Market, by Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Latin America
11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Key Market Developments
11.3.1 Product Launches and Approvals
11.3.2 Acquisitions
11.3.3 Partnerships and Agreements
12 Company Evaluation Matrix and Company Profiles
12.1 Company Evaluation Matrix and Methodology
12.1.1 Competitive Leadership Mapping: Major Market Players (2019)
12.1.2 Visionary Leaders
12.1.3 Innovators
12.1.4 Dynamic Differentiators
12.1.5 Emerging Companies
12.2 Company Evaluation Matrix, 2019
12.3 Company Profiles
12.3.1 Hologic, Inc.
12.3.2 Danaher Corporation
12.3.3 Becton, Dickinson and Company
12.3.4 Argon Medical
12.3.5 Izi Medical Products
12.3.6 Merit Medical Systems
12.3.7 Menarini Silicon Biosystems Spa
12.3.8 Scion Medical Technologies, LLC
12.3.9 Medtronic
12.3.10 Sterylab S.R.L.
12.3.11 Biocept, Inc
12.3.12 Bio-Rad Laboratories, Inc.
12.3.13 F. Hoffmann-La Roche Ltd
12.3.14 Qiagen
12.3.15 Exact Sciences Corporation
12.3.16 Other Companies
12.3.16.1 Thermo Fisher Scientific
12.3.16.2 Cardiff Oncology, Inc.
12.3.16.3 Myriad Genetics, Inc.
12.3.16.4 Illumina, Inc
12.3.16.5 Fluxion Biosciences, Inc.
13 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/82vovh
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article